And by developing its own PD-1 drug the German company hopes to avoid ... Merck to develop combinations with marketed checkpoint inhibitors such Opdivo and Keytruda. Of course the risk is that ...

The PD-1 checkpoint inhibitor was approved back in April 2021 ... But for all that, the drug has yet to be much of a money-maker for the company. Despite GSK's predictions of blockbuster status ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue distribution or immune-related adverse events often limit their application. New ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

For instance, administering chemotherapy with a PD-1 targeting inhibitor called pembrolizumab ... This might involve giving patients immune-boosting drugs or using gene-editing technologies ...

For example, CTLA-4 inhibitors, PD-1 inhibitors and PD-L1 inhibitors. Cancer drugs do not always fit easily into a certain type of treatment. This is because some drugs work in more than one way and ...

However, despite their promise, checkpoint inhibitor therapies tend to work ... including tumors subjected to PD-1-blocking ...